Trial Profile
The Effect of Rifapentine on Plasma Concentrations of Raltegravir.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Rifapentine
- Indications HIV-1 infections; Tuberculosis
- Focus Pharmacokinetics
- 11 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2011 Planned End Date changed from 1 Aug 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.